Has Jacob Kjelland, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,499 in general payments to Jacob Kjelland, MD across 115 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jacob Kjelland, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jacob Kjelland, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jacob Kjelland, MD

Hematology & Oncology · Travis Afb, CANPI 1043604606

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $954 and has fallen 60.2% since, to $380 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.

$2,499in general payments, 2019–2025

Across 115 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$477
Merck$281
E.r. Squibb & Sons, L.L.C.$212
Daiichi Sankyo Inc.$159
Takeda Pharmaceuticals U.S.A., Inc.$153
AbbVie$91
plus $1K from 30 others

What the payments were for

Food & beverage$2,499100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	25	$477
Merck	12	$281
E.r. Squibb & Sons, L.L.C.	10	$212
Daiichi Sankyo Inc.	6	$159
Takeda Pharmaceuticals U.S.A., Inc.	8	$153
AbbVie	3	$91
Astellas Pharma US Inc	4	$85
Bristol Myers Squibb	3	$78
Sanofi	3	$70
Exelixis Inc.	2	$67
Pfizer	2	$64
Incyte Corporation	3	$55
Array Biopharma Inc	2	$53
Mirati Therapeutics, Inc.	2	$46
Sumitomo Pharma America, Inc.	2	$46
Genentech USA, Inc.	2	$46
Novartis	2	$41
Coherus Oncology, Inc.	1	$40
Johnson & Johnson	2	$37
AVEO Pharmaceuticals, Inc.	2	$35
Ipsen Biopharmaceuticals, Inc	2	$32
Deciphera Pharmaceuticals Inc.	2	$31
Amgen	2	$31
Beigene USA, Inc.	1	$30
Beone Medicines USA, Inc.	1	$29
Dendreon Pharmaceuticals LLC	1	$27
Springworks Therapeutics, Inc.	1	$26
Taiho Oncology, Inc.	1	$22
Boehringer Ingelheim	1	$21
EMD Serono, Inc.	1	$21
Servier Pharmaceuticals LLC	1	$20
Myovant Sciences Inc.	1	$19
Polynovo North America LLC	1	$15
Seagen Inc.	1	$14
Morphosys, US Inc.	1	$13
Genmab U.S., Inc.	1	$13

How this compares

$2,499 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024

$13,189

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	12	$173

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Travis Afb

Dennis SlamonLos Angeles$3.1M
Sandra HorningStanford$2.5M
Mohammadbagher ZiariCorona$2.5M
George YaghmourLos Angeles$1.9M
Robert VescioWest Hollywood$1.1M
Kevin KellyLos Angeles$894K
Johnny ChangEncino$884K
Nitin RohatgiSacramento$814K
Omid HamidSanta Monica$809K
Catherine CoombsOrange$786K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →